您的购物车当前为空
Lipoxin A5 (LXA5) is produced by enzymatic transformation of EPA by leukocytes. LXA5 slowly contracts pulmonary parenchymal strips from guinea pig with similar potency to that of LXA4 and LXB4. However, LXA5 does not exert the vasodilatory effects on aortic smooth muscle exhibited by LXA4 and LXB4.
Lipoxin A5 (LXA5) is produced by enzymatic transformation of EPA by leukocytes. LXA5 slowly contracts pulmonary parenchymal strips from guinea pig with similar potency to that of LXA4 and LXB4. However, LXA5 does not exert the vasodilatory effects on aortic smooth muscle exhibited by LXA4 and LXB4.

| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 25 μg | ¥ 6,930 | 35日内发货 | |
| 50 μg | ¥ 13,300 | 35日内发货 | |
| 100 μg | ¥ 25,300 | 35日内发货 |
| 产品描述 | Lipoxin A5 (LXA5) is produced by enzymatic transformation of EPA by leukocytes. LXA5 slowly contracts pulmonary parenchymal strips from guinea pig with similar potency to that of LXA4 and LXB4. However, LXA5 does not exert the vasodilatory effects on aortic smooth muscle exhibited by LXA4 and LXB4. |
| 分子量 | 350.45 |
| 分子式 | C20H30O5 |
| CAS No. | 110657-98-2 |
| Smiles | [C@H]([C@H](CCCC(O)=O)O)(/C=C/C=C/C=C\C=C\[C@H](C/C=C\CC)O)O |
| 存储 | |||||||||||||||||||||||||||||||||||||||||
| 溶解度信息 | PBS (pH 7.2): 1 mg/mL (2.85 mM), Sonication is recommended. Ethanol: 50 mg/mL (142.67 mM), Sonication is recommended. DMF: 50 mg/mL (142.67 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||||||||||||
PBS (pH 7.2)/Ethanol/DMF
Ethanol/DMF
该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。 | |||||||||||||||||||||||||||||||||||||||||
对于不同动物的给药剂量换算,您也可以参考 更多